Nasdaq

60 Degrees Pharmaceuticals Begins Expanded Access Study for Tafenoquine in Immunosuppressed Patients with Relapsing Babesiosis

60 Degrees Pharmaceuticals, Inc. announced the enrollment of the first patient in an expanded access study (NCT06478641) assessing the effectiveness of tafenoquine in treating patients with persistent ...
Seeking Alpha

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite ...

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (SXTP) (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on ...
The Manila Times

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor H…

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...
Nasdaq

Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin

Cognition Therapeutics, Inc. announced the initiation of an expanded access program (EAP) funded by an anonymous philanthropic donation from the family of a patient with dementia with Lewy bodies (DLB ...
Yahoo Finance

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...